Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp.

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2207-2211

  Fernández, Olga ^a   Diaz Toro, Yira ^b   Valderrama, Liliana ^a   Ovalle, Clemencia ^b   Valderrama, Mabel ^a   Castillo, Harry ^a   Perez, Mauricio ^a   Saravia, Nancy Gore ^a  

^a Centro Internacional de Entenamiento e Investigaciones   (Colombia)

^b Instituto de Genética Humana   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; MILTEFOSINE;

ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CELL STRAIN U937; CONCENTRATION RESPONSE; CONTROLLED STUDY; GROWTH INHIBITION; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TEMPERATURE; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA GUYANENESIS; LEISHMANIA PANAMENSIS; MACROPHAGE; NONHUMAN; PARASITE CONTROL; PARASITE ISOLATION; PRIORITY JOURNAL;

ANTIPROTOZOAL AGENTS; CELL LINE; HUMANS; LEISHMANIA; LEISHMANIASIS; MACROPHAGES; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PARASITE LOAD; PARASITIC SENSITIVITY TESTS; PHOSPHORYLCHOLINE; TEMPERATURE;

EID: 84862746487     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00216-12     Document Type: Article

References (24)

1. Berman JD, Neva FA. 1981. Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am. J. Trop. Med. Hyg. 30:318-321.
2. Berman JD, Wyler DJ. 1980. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J. Infect. Dis. 142:83-86.
3. Bryceson A. 2001. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 6:928-934.
4. Carrio J, Portus M. 2002. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacol. 2:11.
5. Croft SL, Sundar S, Fairlamb AH. 2006. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19:111-126.
6. Cruz A, et al. 2007. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J. Infect. Dis. 195:602-608.
7. Dorlo TP, et al. 2008. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob. Agents Chemother. 52:2855-2860.
8. Escobar P, Matu S, Marques C, Croft SL. 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 81:151-157.
9. Gidlund M, et al. 1981. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292:848-850.
10. Goyeneche-Patino DA, Valderrama L, Walker J, Saravia NG. 2008. Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis. Antimicrob. Agents Chemother. 52:4503-4506.
11. Kumar D, Kulshrestha A, Singh R, Salotra P. 2009. In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob. Agents Chemother. 53:835-838.
12. Laurent T, et al. 2007. Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal. Infect. Genet. Evol. 7:206-212.
13. Liu MY, Wu MC. 1992. Induction of human monocyte cell line U937 differentiation and CSF-1 production by phorbol ester. Exp. Hematol. 20:974-979.
14. Lucumi A, Robledo S, Gama V, Saravia NG. 1998. Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes. Antimicrob. Agents Chemother. 42:1990-1995.
15. Rojas R, et al. 2006. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J. Infect. Dis. 193:1375-1383.
16. Romero I, et al. 2010. Viability and burden of Leishmania in extralesional sites during human dermal leishmaniasis. PLoS Negl. Trop. Dis. 4(9):pii=e819.
17. Roy G, et al. 2000. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol. Biochem. Parasitol. 110:195-206.
18. Sanchez-Canete MP, Carvalho L, Perez-Victoria FJ, Gamarro F, Castanys S. 2009. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob. Agents Chemother. 53:1305-1313.
19. Scott P, Sacks D, Sher A. 1983. Resistance to macrophage-mediated killing as a factor influencing the pathogenesis of chronic cutaneous leishmaniasis. J. Immunol. 131:966-971.
20. Seifert K, Escobar P, Croft SL. 2010. In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J. Antimicrob. Chemother. 65:508-511.
21. Vermeersch M, et al. 2009. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob. Agents Chemother. 53:3855-3859.
22. Walker J, et al. 2012. Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol. Biochem. Parasitol. 183:166-176.
23. Yardley V, et al. 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73:272-275.
24. Yardley V, et al. 2006. American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J. Infect. Dis. 194:1168-1175.